Trump Demands Commitments from 17 Big Drugmakers on U.S. Prices

Strategic Insights -

President Trump has directed 17 major pharmaceutical companies to adopt a "most favored nation" policy, which would lower their U.S. prices by committing to international pricing parity. This move is part of an ongoing effort to address high prescription drug prices in the United States. Trump's executive order, issued in May, aims to ensure that American families do not continue to bear the brunt of abusive drug pricing.

Key Takeaways:

  • Trump demanded that 17 big drugmakers, including Novo Nordisk, Eli Lilly, and Pfizer, commit to a "most favored nation" policy to lower U.S. prices within 60 days.
  • The policy would require the companies to adopt international pricing parity, pricing drugs at the lowest level in an OECD country with a GDP per capita of at least 60% of the U.S.
  • The administration aims to "deploy every tool in our arsenal" to protect American families from high drug prices if the companies fail to comply.
  • This move is part of Trump's executive order, issued in May, which aims to address high prescription drug prices in the United States.
  • International pricing parity is a contentious issue, with the trade group PhRMA accusing it of being a form of government price-setting that could have spillover effects on federal health programs.

Statistics:

  • 17 big drugmakers have been directed by Trump to adopt the "most favored nation" policy.
  • The companies have 60 days to commit to the policy.
  • Trump's executive order aims to address high prescription drug prices in the United States.
  • The OECD country with the lowest GDP per capita that is at least 60% of the U.S. is used as a benchmark for international pricing parity.

Sources:

  • [1] Axios: Trump's executive order on May 11, 2025

[2] Axios: Tariffs on the pharmaceutical sector, July 29, 2025

[3] Truth Social: Trump's post on Truth Social, addressing CEOs of pharmaceutical companies

[4] U.S. Department of Health and Human Services: CMS MFS LRP for Lower U.S. Drug Prices (May 2025)

[5] Pharmaceutical Research and Manufacturers of America (PhRMA): Statement on litigation challenging the legality of the administration's most-favored-nation rule